I am a healthcare professional
If you are a healthcare professional looking to find out more about heavy menstrual bleeding and contraception, please click below.
If you are not a healthcare professional and you want to learn about contraception please click below.
If you are not a healthcare professional and you want to learn about heavy menstural bleedingplease click below.
HCP

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

Bayer logo

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

Menstrual Health Coalition: HMB evidence generation

06 November 2019

Supported by industry sponsors (includes funding from Bayer women’s health budget), the Menstrual Health Coalition (MHC) is a group of Members of Parliament, patient and advocacy organisation, life sciences companies, leading clinicians, and individuals who discuss and make recommendations around menstrual health policy. The MHC has a dedicated workstream on heavy menstrual bleeding (HMB).

Following a series of one-on-one meetings with key opinion leaders and parliamentarians, the MHC launched a campaign on 15 July 2019 focused on HMB. The event, held at Westminster, explored the current pathway barriers that women may encounter and ongoing budgetary issues. It was hosted by MHC Chair, Paula Sherriff MP, and featured remarks from Professor Lesley Regan, President of the Royal College of Obstetricians and Gynaecologists, Dr Anne Connolly from the Royal College of General Practitioners, and an independent patient.

To ensure that informed decisions can be taken about treatment options, Professor Lesley Regan stated that, “Women should be empowered with choice, but first, women must be made aware of what their choices are.”

To further highlight the need for open discussion between women and clinicians, the MHC has accompanied the campaign with a Twitter hashtag #TalkingPeriods and launched a call for written evidence on HMB.

For more information on the MHC, please visit: https://www.menstrualhealthcoalition.com/ or follow the hashtag #TalkingPeriods

Recommendations

Online learning

Read more

Upcoming webinars

Read more

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk. Adverse events should also be reported to Bayer plc Tel: 01182063500, Fax: 01182063703, Email: pvuk@bayer.com.


If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.

  • PP-PF-WHC-GB-0276 November 2019

Copyright © 2019,
Bayer plc

This website is intended for UK healthcare professionals only. Women’s Health Matters is organised and funded by Bayer and contains promotional content.

Prescribing Information (PI) can be found via the links below:
Mirena® (52 mg intrauterine delivery system Levonorgestrel)
Kyleena® (19.5 mg intrauterine delivery system Levonorgestrel)
Jaydess® (13.5 mg intrauterine delivery system Levonorgestrel)
Qlaira® (estradiol valerate/dienogest)
Microgynon® (levonorgestrel/ethinylestradiol)

Page last modified Tue, 12/10/2019 - 06:09

Bayer logo